Inotersen inhibits the production of amyloid in patients with the rare disorder.
The safety profile was fairly similar to that seen with intravenous formulations.
Daily News Podcast
And beware a nasty skin souvenir from travel abroad.
From the Journals
A pivotal phase 2/3 trial of bertilimumab will begin next year, according to the company.